About 338,000 Tricare patients who have a Nexium prescription are being asked to switch to an alternative drug for their stomach and esophagus problems. As of June 28, Nexium will no longer be ...

TRENTON, N.J. (AP) -- Drugmakers AstraZeneca PLC and Pfizer Inc. have reached a deal giving Pfizer future rights to sell a nonprescription version of AstraZeneca's blockbuster heartburn drug, Nexium, ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. INDEPENDENCE, Mo. — One of the most popular ...

In a price-slashing move that could mark the first of several cuts to its pharmaceutical budget, the Pentagon is dropping AstraZeneca’s heartburn drug Nexium from the list of drugs it covers for ...

correctionA May 8 article misstated the amount of money spent in 2004 advertising the heartburn medication Nexium. The correct figure is $200 million, not $2.2 million. (Published 5/19/2005) Beginning ...

Pharmaceutical giant AstraZeneca will pay the government $7.9 million to settle allegations that it engaged in a kickback scheme regarding its drug Nexium, the U.S. Department of Justice announced on ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

The Food and Drug Administration has approved use of the drug Nexium in children aged 1 to 11 who have acid reflux disease. FDA said Thursday it approved liquid and delayed-release capsules of Nexium ...

Pharmaceutical companies usually provide innovation that helps improve the lives of patients. But AstraZeneca marketed Nexium, a drug that should have never been approved in the first place. The ...

LONDON, July 1 (Reuters) - AstraZeneca's blockbuster heartburn and ulcer drug Nexium has finally been approved in Japan, giving it a new lease of life just as it faces generic competition in some ...

CHICAGO -- U.S. employers, struggling to tame double-digit health inflation, are putting the squeeze on AstraZeneca's ulcer drug Nexium, a product the Anglo-Swedish drug maker sorely needs to boost ...

AstraZeneca (NYSE:AZN) raised its 2014 sales forecast for the second quarter in a row on Thursday, as the delayed arrival of generic copies of its Nexium drug in the United States kept cash flowing ...